BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

141 related articles for article (PubMed ID: 36511451)

  • 1. Relapses of multisystem/multifocal bone Langerhans cell histiocytosis in paediatric patients: Data analysis from the JLSG-96/02 study.
    Sakamoto K; Morimoto A; Shioda Y; Imamura T; Imashuku S;
    Br J Haematol; 2023 Mar; 200(6):769-775. PubMed ID: 36511451
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Intensification of induction therapy and prolongation of maintenance therapy did not improve the outcome of pediatric Langerhans cell histiocytosis with single-system multifocal bone lesions: results of the Japan Langerhans Cell Histiocytosis Study Group-02 Protocol Study.
    Morimoto A; Shioda Y; Imamura T; Kudo K; Kitoh T; Kawaguchi H; Goto H; Kosaka Y; Tsunematsu Y; Imashuku S;
    Int J Hematol; 2018 Aug; 108(2):192-198. PubMed ID: 29594922
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Treatment of children with multiple system Langerhans cell histiocytosis by Japan Langerhans Cell Histiocytosis Study Group Protocol].
    Huang JB; Xue HM; Chen YY; Huang K
    Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2013 Feb; 21(1):146-9. PubMed ID: 23484709
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Central diabetes insipidus in pediatric patients with Langerhans cell histiocytosis: Results from the JLSG-96/02 studies.
    Sakamoto K; Morimoto A; Shioda Y; Imamura T; Imashuku S;
    Pediatr Blood Cancer; 2019 Jan; 66(1):e27454. PubMed ID: 30207064
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Intensified and prolonged therapy comprising cytarabine, vincristine and prednisolone improves outcome in patients with multisystem Langerhans cell histiocytosis: results of the Japan Langerhans Cell Histiocytosis Study Group-02 Protocol Study.
    Morimoto A; Shioda Y; Imamura T; Kudo K; Kawaguchi H; Sakashita K; Yasui M; Koga Y; Kobayashi R; Ishii E; Fujimoto J; Horibe K; Bessho F; Tsunematsu Y; Imashuku S
    Int J Hematol; 2016 Jul; 104(1):99-109. PubMed ID: 27040279
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Outcome of pediatric patients with Langerhans cell histiocytosis treated with 2 chlorodeoxyadenosine: a nationwide survey in Japan.
    Imamura T; Sato T; Shiota Y; Kanegane H; Kudo K; Nakagawa S; Nakadate H; Tauchi H; Kamizono J; Morimoto A
    Int J Hematol; 2010 May; 91(4):646-51. PubMed ID: 20361277
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Improved outcome in the treatment of pediatric multifocal Langerhans cell histiocytosis: Results from the Japan Langerhans Cell Histiocytosis Study Group-96 protocol study.
    Morimoto A; Ikushima S; Kinugawa N; Ishii E; Kohdera U; Sako M; Fujimoto J; Bessho F; Horibe K; Tsunematsu Y; Imashuku S;
    Cancer; 2006 Aug; 107(3):613-9. PubMed ID: 16804933
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Bone lesions of Langerhans cell histiocytosis triggered by trauma in children.
    Morimoto A; Shioda Y; Sakamoto K; Imamura T; Imashuku S;
    Pediatr Int; 2022 Jan; 64(1):e15199. PubMed ID: 35770832
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Clinical and prognostic characteristics of 95 cases of Langerhans cell histiocytosis in children: a single-institute experience from 2013 to 2020.
    Tang X; Gao J; Ma ZG; Guo X; Li Q; Wan Z; Sun JJ
    Ann Med; 2021 Dec; 53(1):1537-1546. PubMed ID: 34459688
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Treatment of multisystem Langerhans cell histiocytosis. Results of the DAL-HX 83 and DAL-HX 90 studies. DAL-HX Study Group.
    Minkov M; Grois N; Heitger A; Pötschger U; Westermeier T; Gadner H
    Klin Padiatr; 2000; 212(4):139-44. PubMed ID: 10994540
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Outcome Comparison of Pediatric Langerhans Cell Histiocytosis Treated with Modified DAL-HX83/90 or JLSG-96 Protocol].
    Huang JB; Jiang L; Chen C; Xue HM
    Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2016 Aug; 24(4):1190-5. PubMed ID: 27531798
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Intensification of treatment with vinca alkaloid does not improve outcomes in pediatric patients with Langerhans cell histiocytosis: results from the JPLSG LCH-12 study.
    Morimoto A; Shioda Y; Kudo K; Kanegane H; Imamura T; Koh K; Kosaka Y; Yuza Y; Nakazawa A; Saito AM; Watanabe T; Nakazawa Y
    Int J Hematol; 2023 Jul; 118(1):107-118. PubMed ID: 36871086
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Analysis of 43 cases of Langerhans cell histiocytosis (LCH)-induced central diabetes insipidus registered in the JLSG-96 and JLSG-02 studies in Japan.
    Shioda Y; Adachi S; Imashuku S; Kudo K; Imamura T; Morimoto A
    Int J Hematol; 2011 Dec; 94(6):545-51. PubMed ID: 22139588
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Long-term complications in uniformly treated paediatric Langerhans histiocytosis patients disclosed by 12 years of follow-up of the JLSG-96/02 studies.
    Sakamoto K; Morimoto A; Shioda Y; Imamura T; Imashuku S;
    Br J Haematol; 2021 Feb; 192(3):615-620. PubMed ID: 33236384
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Langerhans cell histiocytosis of the temporal bone: A review of 29 cases at a single center.
    Modest MC; Garcia JJ; Arndt CS; Carlson ML
    Laryngoscope; 2016 Aug; 126(8):1899-904. PubMed ID: 26535795
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Pediatric langerhans cell histiocytosis: single center experience over a 17-year period.
    İnce D; Demirağ B; Özek G; Erbay A; Ortaç R; Oymak Y; Kamer S; Yaman Y; Kundak S; Vergin C
    Turk J Pediatr; 2016; 58(4):349-355. PubMed ID: 28276205
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Craniofacial involvement in Langerhans cell histiocytosis: A review of 44 cases at a single medical center.
    Lin TE; Chu YY; Chang TY; Liao HT
    J Plast Reconstr Aesthet Surg; 2023 Jul; 82():12-20. PubMed ID: 37148805
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Multisystem Langerhans cell histiocytosis in children: current treatment and future directions.
    Minkov M
    Paediatr Drugs; 2011 Apr; 13(2):75-86. PubMed ID: 21351807
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Langerhans cell histiocytosis with multifocal bone lesions: comparative clinical features between single and multi-systems.
    Imashuku S; Kinugawa N; Matsuzaki A; Kitoh T; Ohki K; Shioda Y; Tsunematsu Y; Imamura T; Morimoto A;
    Int J Hematol; 2009 Nov; 90(4):506-512. PubMed ID: 19779766
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Outcome of children with Langerhans cell histiocytosis and single-system involvement: A retrospective study at a single center in Shanghai, China.
    Su M; Gao YJ; Pan C; Chen J; Tang JY
    Pediatr Hematol Oncol; 2018; 35(7-8):385-392. PubMed ID: 30693828
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.